Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations:  II. Therapies for allergic bronchopulmonary aspergillosis

This review is the second article in the State‐of‐the‐Art series and aims to evaluate medications used in the treatment of allergic bronchopulmonary aspergillosis (ABPA) in pediatric and adult patients with cystic fibrosis (CF). ABPA is one of several organisms that are found in the airways of CF pa...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric pulmonology 2020-12, Vol.55 (12), p.3541-3572
Main Authors: Epps, Quovadis J., Epps, Kevin L., Zobell, Jeffery T., Young, David C.
Format: Article
Language:English
Subjects:
ABPA
Adolescent
Adrenal Cortex Hormones - therapeutic use
Adult
Amphotericin B - therapeutic use
Anti-Infective Agents - therapeutic use
Antibodies, Monoclonal - therapeutic use
Antifungal agents
Antifungal Agents - therapeutic use
anti‐fungal therapy
Aspergillosis
Aspergillosis, Allergic Bronchopulmonary - drug therapy
Child
corticosteroids
Cystic fibrosis
Cystic Fibrosis - complications
Cystic Fibrosis - drug therapy
Female
Fungal infections
Humans
Itraconazole - therapeutic use
Monoclonal antibodies
Omalizumab - therapeutic use
Pharmacology
Voriconazole - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This review is the second article in the State‐of‐the‐Art series and aims to evaluate medications used in the treatment of allergic bronchopulmonary aspergillosis (ABPA) in pediatric and adult patients with cystic fibrosis (CF). ABPA is one of several organisms that are found in the airways of CF patients. This review provides an evidence‐based summary of pharmacokinetic (PK)/pharmacodynamic (PD), tolerability, and efficacy studies of medications including corticosteroids, amphotericin B, azole antifungals (isavuconazole, itraconazole, posaconazole, and voriconazole), and a monoclonal antibody omalizumab in the treatment of ABPA and identifies areas where further study is warranted.
ISSN:8755-6863
1099-0496
DOI:10.1002/ppul.25080